$SGHT News

Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $5.15

Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript

Sight Sciences Raises FY2026 Sales Guidance from $82.000M-$88.000M to $83.000M-$89.000M vs $84.695M Est

Sight Sciences Q1 EPS $(0.24) Misses $(0.18) Estimate, Sales $19.700M Beat $18.544M Estimate

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Sight Sciences To Present Data On Two Of Its Proprietary Glaucoma And Dry Eye Technologies, OMNI Surgical System And TearCare System, At 2026 ASCRS Annual Meeting

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

U.S. District Court Preserves Jury's Willful Infringement Verdict In Sight Sciences Case Vs Alcon

Citigroup Maintains Neutral on Sight Sciences, Lowers Price Target to $6.5

Sight Sciences, Inc. Q4 2025 Earnings Call Summary

Sight Sciences shares are trading lower after the company reported worse-than-expected Q4 sales results.

Sight Sciences shares are trading lower after the company reported worse-than-expected Q4 sales results.

Sight Sciences Inc (SGHT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Sight Sciences Q4 Earnings Call Highlights

Sight Sciences Inc (NASDAQ:SGHT) Reports Mixed Q4 2025 Results, Beats on EPS but Misses Revenue

Sight Sciences (SGHT) Q4 2025 Earnings Transcript

Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates